

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

05 FEB 14 PM 5:13

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name O'Connor & Hannan, L.L.P.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1666 K Street, N.W. Suite 500 City Washington State/Zip (or Country) DC 20006			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Timothy W. Jenkins		Telephone (202) 887-1400	E-mail (optional) _____
5. Senate ID # 29846-1992			
7. Client Name <input type="checkbox"/> Self Merck & Co., Inc.			6. House ID # 30352156

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☐


9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____

11. No Lobbying ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$40,000.00</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of method.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 603 of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162 of the Internal Revenue Code</p>
--	--

Signature  _____ Date _____

Printed Name and Title **Timothy W. Jenkins - Partner** _____ P

Client Name: Merck & Co., Inc.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

H.R. 1 Medicare Prescription Drug and Modernization Act of 2003 (including reimportation provisions); H. Pharmaceutical Market Access of 2003; S. 1 Prescription Drug and Medicare Improvement Act of 2003; Drug Importation Promotion and Safety Act (Introduced in House)[H.R.4790.IH]; Safe IMPORT Act of 2004 (Introduced in House)[H.R.4923.IH]; To amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs. (Introduced in House)[H.R.3710.IH]; Expressing the sense of the Congress that the illegal importation of prescription drugs severely undermines the regulatory protections afforded to United States consumers, and other... (Introduced in House)[H.CON.RES.225.IH]; Vioxx withdrawal, FDA Safety Issues; Save Our Seniors Act (Introduced in House)[H.R.2769.IH]; Prescription Drug Parity for Americans Act (Introduced in House)[H.R.2769.IH]; Affordable Medicine Safety and Access Act (Introduced in House)[H.R.2717.IH]; Reliable Entry for Medicines Act (Introduced in House)[H.R.2717.IH]; Everyday Discounts through Importation with Effective Safeguards Act of 2004 (Introduced in Senate)[S.231]

17. House(s) of Congress and Federal agencies contacted

House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

[illegible]

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 4/11/2005

Printed Name and Title Timothy W. Jenkins - Partner 1

Registrant Name: O'Connor & Hannan, L.L.P.

Client Name: Merck & Co., Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific Lobbying issues

H.R. 1 Medicare Prescription Drug and Modernization Act of 2003 (including reimportation provisions); H. Pharmaceutical Market Access of 2003; S. 1 Prescription Drug and Medicare Improvement Act of 2003; Drug Importation Promotion and Safety Act (Introduced in House)[H.R.4790.IH]; Safe IMPORT Act of 2004 (Introduced in House)[H.R.4923.IH]; To amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs. (Introduced in House)[H.R.3710.IH]; Expressing the sense of the Congress that the illegal sale of prescription drugs severely undermines the regulatory protections afforded to United States consumers, and to encourage the development of new drugs. (Introduced in House)[H.CON.RES.225.IH]; Save Our Seniors Act of 2003 (Introduced in House)[H.R.2497.IH]; Affordable Medicine Safe Act (Introduced in House)[H.R.2717.IH]; Reliable Entry for Medicines at Everyday Discounts through Importation (Introduced in Senate)[S.2307.IS];

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Jenkins, Timothy W.	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date _____

Printed Name and Title **Timothy W. Jenkins - Partner** _____ Page _____